DK0832211T3 - Oligonucleotider, der er specifikke for hepatitis B-virus. - Google Patents

Oligonucleotider, der er specifikke for hepatitis B-virus.

Info

Publication number
DK0832211T3
DK0832211T3 DK96918671T DK96918671T DK0832211T3 DK 0832211 T3 DK0832211 T3 DK 0832211T3 DK 96918671 T DK96918671 T DK 96918671T DK 96918671 T DK96918671 T DK 96918671T DK 0832211 T3 DK0832211 T3 DK 0832211T3
Authority
DK
Denmark
Prior art keywords
hepatitis
virus
oligonucleotides specific
hbv
kits
Prior art date
Application number
DK96918671T
Other languages
English (en)
Inventor
Robert E Kilkuskie
John Goodchild
Charles J Craig
Bruce L Frank
Raymond Jupp
John S Mills
Noel A Roberts
Peter C Roberts
Andrew Slade
Original Assignee
Hybridon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hybridon Inc filed Critical Hybridon Inc
Application granted granted Critical
Publication of DK0832211T3 publication Critical patent/DK0832211T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • C12N2310/313Phosphorodithioates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • C12N2310/314Phosphoramidates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • C12N2310/315Phosphorothioates
DK96918671T 1995-06-06 1996-06-04 Oligonucleotider, der er specifikke for hepatitis B-virus. DK0832211T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46739795A 1995-06-06 1995-06-06
PCT/EP1996/002432 WO1996039502A1 (en) 1995-06-06 1996-06-04 Oligonucleotides specific for hepatitis b virus

Publications (1)

Publication Number Publication Date
DK0832211T3 true DK0832211T3 (da) 2003-05-26

Family

ID=23855522

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96918671T DK0832211T3 (da) 1995-06-06 1996-06-04 Oligonucleotider, der er specifikke for hepatitis B-virus.

Country Status (10)

Country Link
US (2) US5856459A (da)
EP (1) EP0832211B1 (da)
AT (1) ATE233318T1 (da)
AU (1) AU6125296A (da)
CA (1) CA2226458A1 (da)
DE (1) DE69626393T2 (da)
DK (1) DK0832211T3 (da)
ES (1) ES2188760T3 (da)
WO (1) WO1996039502A1 (da)
ZA (1) ZA964445B (da)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040054156A1 (en) * 1992-05-14 2004-03-18 Kenneth Draper Method and reagent for inhibiting hepatitis B viral replication
US5646262A (en) 1994-07-28 1997-07-08 Georgetown University Antisense oligonucleotides against hepatitis B viral replication
US5985662A (en) * 1995-07-13 1999-11-16 Isis Pharmaceuticals Inc. Antisense inhibition of hepatitis B virus replication
JP4091663B2 (ja) 1996-10-31 2008-05-28 バイオジェン アイデック マサチューセッツ インコーポレイテッド B型肝炎インヒビター
CN1057302C (zh) * 1997-08-27 2000-10-11 中国科学院上海生物化学研究所 抑制乙型肝炎病毒复制的反义脱氧寡核苷酸
CN1215058A (zh) * 1997-10-21 1999-04-28 中国科学院上海生物化学研究所 新的三链形成寡核苷酸结构及其在抗乙肝病毒中的应用
WO2000032625A1 (en) 1998-12-04 2000-06-08 Biogen, Inc. Hbv core antigen particles with multiple immunogenic components attached via peptide ligands
AU2001254670A1 (en) * 2000-03-02 2001-09-12 Akzo Nobel N.V. Detection of hepatitis b virus rna
US6583279B1 (en) 2001-01-26 2003-06-24 Becton, Dickinson And Company Sequences and methods for detection of hepatitis B virus
CA2442092A1 (en) * 2001-03-26 2002-10-17 Ribozyme Pharmaceuticals, Inc. Oligonucleotide mediated inhibition of hepatitis b virus and hepatitis c virus replication
WO2002092006A2 (en) 2001-05-16 2002-11-21 Micrologix Biotech, Inc. Nucleic acid-based compounds and methods of use thereof
US20030140362A1 (en) * 2001-06-08 2003-07-24 Dennis Macejak In vivo models for screening inhibitors of hepatitis B virus
EP1513958B1 (en) * 2002-06-14 2011-08-10 Gen-Probe Incorporated Compositions for detecting hepatitis b virus
EP1403385A1 (en) * 2002-09-27 2004-03-31 Institut National De La Sante Et De La Recherche Medicale (Inserm) Method for assaying replication of HBV and testing susceptibility to drugs
PT2241325E (pt) * 2002-10-29 2012-04-12 Coley Pharm Gmbh Utilização de oligonucleótidos cpg no tratamento de infecção com vírus da hepatite c
EA201290152A1 (ru) 2009-10-16 2012-12-28 Глаксо Груп Лимитед Антисмысловые ингибиторы вируса гепатита в (hbv)
RU2667524C2 (ru) * 2011-04-21 2018-09-21 Ионис Фармасьютикалз, Инк. Модулирование экспрессии вируса гепатита b (hbv)
CN113430196A (zh) 2011-06-30 2021-09-24 箭头药业股份有限公司 用于抑制乙型肝炎病毒的基因表达的组合物和方法
GB201408623D0 (en) 2014-05-15 2014-07-02 Santaris Pharma As Oligomers and oligomer conjugates
CA2991639A1 (en) 2015-08-07 2017-02-16 Arrowhead Pharmaceuticals, Inc. Rnai therapy for hepatitis b virus infection
JOP20170161A1 (ar) 2016-08-04 2019-01-30 Arrowhead Pharmaceuticals Inc عوامل RNAi للعدوى بفيروس التهاب الكبد ب
KR102273071B1 (ko) * 2018-06-12 2021-07-05 주식회사 에이엠사이언스 B형 간염 예방 또는 치료용 조성물
WO2019240504A1 (en) * 2018-06-12 2019-12-19 Am Sciences Co., Ltd. Modified oligonucleotides for inhibition of target gene expression

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225326A (en) * 1988-08-31 1993-07-06 Research Development Foundation One step in situ hybridization assay
US5610050A (en) * 1990-04-20 1997-03-11 The General Hospital Corporation Methods of preventing viral replication
AU662304B2 (en) * 1990-10-22 1995-08-31 Fox Chase Cancer Center DNA construct for providing RNA therapy
KR100252547B1 (ko) * 1991-09-05 2000-09-01 프레드 마리얀스키 폴리-또는 올리고누클레오티드의 세포로의 표적화된 전달
US5585479A (en) * 1992-07-24 1996-12-17 The United States Of America As Represented By The Secretary Of The Navy Antisense oligonucleotides directed against human ELAM-I RNA
WO1995017414A1 (en) * 1993-12-23 1995-06-29 Apollon, Inc. Anti-hepatitis b viral oligonucleotides
US5728518A (en) * 1994-01-12 1998-03-17 The Immune Response Corporation Antiviral poly-and oligonucleotides
US5646262A (en) * 1994-07-28 1997-07-08 Georgetown University Antisense oligonucleotides against hepatitis B viral replication

Also Published As

Publication number Publication date
DE69626393D1 (de) 2003-04-03
AU6125296A (en) 1996-12-24
ATE233318T1 (de) 2003-03-15
ZA964445B (en) 1996-12-06
US5856459A (en) 1999-01-05
DE69626393T2 (de) 2003-12-04
WO1996039502A1 (en) 1996-12-12
EP0832211B1 (en) 2003-02-26
ES2188760T3 (es) 2003-07-01
CA2226458A1 (en) 1996-12-12
EP0832211A1 (en) 1998-04-01
US6984729B1 (en) 2006-01-10

Similar Documents

Publication Publication Date Title
DK0832211T3 (da) Oligonucleotider, der er specifikke for hepatitis B-virus.
DE69403642T2 (de) 7-deazapurin modifizierte oligonukleotide
ATE289519T1 (de) Zusammensetzungen und verfahren zur behandlung von hepatitis c virus-bedingten erkrankungen
NO983716L (no) Metoksyetoksy oligonukleotider for modulering av protein-kinase C ekspresjon
DE68925278D1 (de) Hemmung von htlv-iii durch exogene oligonukleotide
DE69803391D1 (de) Zusammensetzung die mindestens ein doppel strangiges rna und mindestens ein interferon enthält, zur behandlung von virale hepatitis
ATE355380T1 (de) Methode zur selektiven inaktivierung der viralen replication
DE69330372T2 (de) ZUSAMMENSETZUNGEN UND VERFAHREN FüR DIE BEHANDLUNG VON MIT HEPATITIS C VIREN ASSOZIIERTEN KRANKHEITEN
BR9502707A (pt) Composto composição farmacêutica e método para o tratamento de uma afecção
TR200003036T2 (tr) 12,13-Modifiye edilmiş epotilon türevleri
ES2196181T3 (es) Derivados de purina y proceso para su preparacion.
DK0966447T3 (da) Anvendelige små molekyler til behandling af betændelsessygdomme
DE69940371D1 (de) Beta-glucan enthaltende zusammenstellungen und spezifische immunoglobuline
DE60001770D1 (de) Verfahren zur Herstellung von eigenleitfähigen Copolymeren und damit hergestellte eigenleitfähige Copolymer-Verbindungen
ATE298741T1 (de) Polyaromatische verbindungen zur behandlung von herpes-infektionen
DK1123414T3 (da) Antisense-modulering af integrin alpha 4.ekspression
DE69831000D1 (de) Verwendung von cytidin und cytosin-enthaltenden verbindungen zur behandlung von reizmittelgelgebrauch
ATE173466T1 (de) Verbindungen und methoden zur inhibition von hiv und verwandten viren
NO904901D0 (no) N-substituerte derivater av 3r,4r-etyl-((1-metyl-1h-imidazol-5-yl)metyl) -2-pyrrolidinon.
PT1023310E (pt) Sintese melhorada de oligonucleotidos sulfurados
ES2091928T3 (es) Metodos de prevencion de la replicacion virica.
NL1007469A1 (nl) Proces voor de productie van acrylonitril.
WO1996039500A3 (en) Oligonucleotides specific for hepatitis c virus
WO1996039501A3 (en) Oligonucleotides specific for human papillomavirus
DE69922364D1 (de) Verfahren zur immunisierung und behandlung von h. pylori infektion